ArticleBlood advances2019
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer.Cancer research · 2026Article
- Inhibition of pyrimidine de novo synthesis fosters Treg cells and reduces diabetes development in models of Type 1 Diabetes.Molecular metabolism · 2025Article
- Individualized dynamic risk assessment and treatment selection for multiple myeloma.British journal of cancer · 2025Article
- The DHODH inhibitor teriflunomide impedes cell proliferation and enhances chemosensitivity to daunorubicin (DNR) in T-cell acute lymphoblastic leukemia.Annals of hematology · 2024Article
- A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.Annals of hematology · 2024Article
- Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma.Hematology. American Society of Hematology. Education Program · 2022Article
- Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression.The Journal of clinical investigation · 2022Article
- Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review.Dermatology and therapy · 2022Review
- Teriflunomide - The common drug with underestimated oxygen - Dependent anticancer potential.Biochemistry and biophysics reports · 2021Article
- The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line.Molecules (Basel, Switzerland) · 2021Article
- Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.Journal of hematology & oncology · 2021Article
- Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.International immunopharmacology · 2021Review
- Review
- MYC inhibitors in multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Inhibition ofInternational journal of biological sciences · 2021Article
- Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study.Leukemia & lymphoma · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 3 institutions in 1 country.
Ralf BuettnerDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Corey MoralesDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Enrico CasertaDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Estelle TroadecDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Emine G GunesDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Domenico ViolaDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Jihane KhalifeDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Hongzhi LiDepartment of Computational and Quantitative Medicine, City of Hope, Duarte, CA.
Jonathan J KeatsIntegrated Cancer Genomics, Translational Genomics Research Institute, Phoenix, AZ; and.
Austin ChristoffersonIntegrated Cancer Genomics, Translational Genomics Research Institute, Phoenix, AZ; and.
Xiwei WuIntegrative Genomics Core, Department of Molecular Medicine, Beckman Research Institute.
Timothy W SynoldDepartment of Cancer Biology, Beckman Research Institute, and.
Joycelynne PalmerDepartment of Computational and Quantitative Medicine, City of Hope, Duarte, CA.
James F SanchezDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Alexander PozhitkovDepartment of Computational and Quantitative Medicine, City of Hope, Duarte, CA.
Nagarajan VaidehiDepartment of Computational and Quantitative Medicine, City of Hope, Duarte, CA.
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, Duarte, CA.
Amrita KrishnanDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Michael A RosenzweigDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Flavia PichiorriDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
Steven T RosenDepartment of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematologic Malignancies and Stem Cell Transplantation Institute, and.
City of Hope · USBeckman Research InstituteTranslational Genomics Research Institute · US
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3MOvercoming IMiD resistance in MyelomaR01CA201382 · NCI · OHIO STATE UNIVERSITY · PI HOFMEISTER, CRAIG C., PHELPS, MITCH A · 2016 to 2020
$2.6MNCI NIH HHS P30 CA033572NCI NIH HHS R01 CA201382
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsDrug SynergismDrug Therapy, CombinationEnzyme InhibitorsHumansLeflunomideLenalidomideMiceMultiple MyelomaProto-Oncogene Proteins c-mycProto-Oncogene Proteins c-pim-1Tumor Cells, CulturedEnzyme InhibitorsLeflunomideLenalidomideProto-Oncogene Proteins c-mycProto-Oncogene Proteins c-pim-1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.